The translocator protein radioligand 18F-DPA-714 monitors antitumor effect of erufosine in a Rat 9L intracranial glioma model

Journal of Nuclear Medicine

Volumn 54, Issue 12, 2013, Pages 2125-2131

  Awde, Ali R ^a,b   Boisgard, Raphaël ^a,b   Thézé, Benoit ^a,b   Dubois, Albertine ^a,b   Zheng, Jinzi ^a,b   Dollé, Frédéric ^a   Jacobs, Andreas H ^c   Tavitian, Bertrand ^a,b,d   Winkeler, Alexandra ^a,b  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

ErPC3; Glioma; TSPO

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CD11B ANTIGEN; ERUFOSINE; GLIAL FIBRILLARY ACIDIC PROTEIN; N,N DIETHYL 2 [2 [4 (2 FLUOROETHOXY)PHENYL] 5,7 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDIN 3 YL]ACETAMIDE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID A RECEPTOR; BZRP PROTEIN, RAT; CARRIER PROTEIN; DIAGNOSTIC AGENT; ERUCYLPHOSPHO N,N,N TRIMETHYLPROPYLAMMONIUM; ERUCYLPHOSPHO-N,N,N-TRIMETHYLPROPYLAMMONIUM; FLUORINE; N,N DIETHYL 2 (2 (4 (2 FLUOROETHOXY)PHENYL) 5,7 DIMETHYLPYRAZOLO(1,5 A)PYRIMIDIN 3 YL)ACETAMIDE; N,N-DIETHYL-2-(2-(4-(2-FLUOROETHOXY)PHENYL)-5,7-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDIN-3-YL)ACETAMIDE; ORGANOPHOSPHATE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUATERNARY AMMONIUM DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; GLIOMA CELL LINE; GLIOSARCOMA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MICROGLIA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; TUMOR MODEL; TUMOR VOLUME; 18F-DPA-714; ANIMAL; APOPTOSIS; BRAIN; BRAIN TUMOR; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECT; ERPC3; GENE EXPRESSION REGULATION; GLIOBLASTOMA; GLIOMA; MALE; METABOLISM; PATHOLOGY; SCINTISCANNING; TREATMENT OUTCOME; TSPO; TUMOR CELL LINE; BRAIN NEOPLASMS; DIAGNOSTIC USE; DRUG EFFECTS;

18F-DPA-714; ERPC3; GLIOMA; TSPO;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN; BRAIN NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FLUORINE RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; MALE; ORGANOPHOSPHATES; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; PYRIMIDINES; QUATERNARY AMMONIUM COMPOUNDS; RATS; RECEPTORS, GABA-A; TREATMENT OUTCOME;

EID: 84893397267     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.118794     Document Type: Article

References (39)

1. Papadopoulos V, Baraldi M, Guilarte TR, et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27:402-409.
2. Winkeler A, Boisgard R, Martin A, Tavitian B. Radioisotopic imaging of neuroinflammation. J Nucl Med. 2010;51:1-4.
3. Chen MK, Guilarte TR. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair. Pharmacol Ther. 2008;118:1-17.
4. Batarseh A, Papadopoulos V. Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states. Mol Cell Endocrinol. 2010;327:1-12.
5. Galiègue S, Casellas P, Kramar A, Tinel N, Simony-Lafontaine J. Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival. Clin Cancer Res. 2004;10:2058-2064.
6. Vlodavsky E, Soustiel JF. Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival. J Neurooncol. 2007;81:1-7.
7. Miettinen H, Kononen J, Haapasalo H, et al. Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: relationship to cell proliferation. Cancer Res. 1995;55:2691-2695.
8. Rechichi M, Salvetti A, Chelli B, et al. TSPO over-expression increases motility, transmigration and proliferation properties of C6 rat glioma cells. Biochim Biophys Acta. 2008;1782:118-125.
9. Jacobs AH, Tavitian B. Noninvasive molecular imaging of neuroinflammation. J Cereb Blood Flow Metab. 2012;32:1393-1415.
10. James ML, Fulton RR, Vercoullie J, et al. DPA-714, a new translocator proteinspecific ligand: synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med. 2008;49:814-822.
11. Abourbeh G, Theze B, Maroy R, et al. Imaging microglial/macrophage activation in spinal cords of experimental autoimmune encephalomyelitis rats by positron emission tomography using the mitochondrial 18 kDa translocator protein radioligand [18F]DPA-714. J Neurosci. 2012;32:5728-5736.
12. Winkeler A, Boisgard R, Awde AR, et al. The translocator protein ligand [18F] DPA-714 images glioma and activated microglia in vivo. Eur J Nucl Med Mol Imaging. 2012;39:811-823.
13. Tang D, Hight MR, McKinley ET, et al. Quantitative preclinical imaging of TSPO expression in glioma using N,N-diethyl-2-(2-(4-(2-18F-fluoroethoxy) phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimi din-3-yl)acetamide. J Nucl Med. 2012;53:287-294.
14. Buck JR, McKinley ET, Hight MR, et al. Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5- dimethoxybenzyl)- 2-phenoxyaniline. J Nucl Med. 2011;52:107-114.
15. Kugler W, Veenman L, Shandalov Y, et al. Ligands of the mitochondrial 18 kDa translocator protein attenuate apoptosis of human glioblastoma cells exposed to erucylphosphohomocholine. Cell Oncol. 2008;30:435-450.
16. Jendrossek V, Muller I, Eibl H, Belka C. Intracellular mediators of erucylphosphocholine- induced apoptosis. Oncogene. 2003;22:2621-2631.
17. Jendrossek V, Erdlenbruch B, Hunold A, Kugler W, Eibl H, Lakomek M. Erucylphosphocholine, a novel antineoplastic ether lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro. Int J Oncol. 1999;14:15-22.
18. Erdlenbruch B, Jendrossek V, Marx M, Hunold A, Eibl H, Lakomek M. Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo. Anticancer Res. 1998;18:2551-2557.
19. Erdlenbruch B, Jendrossek V, Gerriets A, Vetterlein F, Eibl H, Lakomek M. Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. Cancer Chemother Pharmacol. 1999;44:484-490.
20. Henke G, Lindner L, Vogeser M, et al. Pharmacokinetics and biodistribution of Erufosine in nude mice - implications for combination with radiotherapy. Radiat Oncol. 2009;4:46.
21. Bagley RG, Kurtzberg L, Rouleau C, Yao M, Teicher BA. Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells. Cancer Chemother Pharmacol. 2011;68:1537-1546.
22. Rudner J, Ruiner C-E, Handrick R, Eibl H-J, Belka C, Jendrossek V. The Aktinhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol. 2010;5:108.
23. Lemeshko VV, Kugler W. Synergistic inhibition of mitochondrial respiration by anticancer agent erucylphosphohomocholine and cyclosporin A. J Biol Chem. 2007;282:37303-37307.
24. Levin E, Premkumar A, Veenman L, et al. The peripheral-type benzodiazepine receptor and tumorigenicity: isoquinoline binding protein (IBP) antisense knockdown in the C6 glioma cell line. Biochemistry. 2005;44:9924-9935.
25. Kuhnast B, Damont A, Hinnen F, et al. [18F]DPA-714, [18F]PBR111 and [18F] FEDAA1106-selective radioligands for imaging TSPO 18 kDa with PET: automated radiosynthesis on a TRACERLAb FX-FN synthesizer and quality controls. Appl Radiat Isot. 2012;70:489-497.
26. Cízek J, Herholz K, Vollmar S, Schrader R, Klein J, Heiss WD. Fast and robust registration ofPETandMRimages ofhumanbrain. Neuroimage. 2004;22:434-442.
27. Lamprecht MR, Sabatini DM, Carpenter AE. CellProfiler: free, versatile software for automated biological image analysis. Biotechniques. 2007;42:71-75.
28. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics International.. 2004;11:36-42.
29. Chauveau F, Van Camp N, Dolle F, et al. Comparative evaluation of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation. J Nucl Med. 2009;50:468-476.
30. Rübel A, Handrick R, Lindner L, et al. The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiat Oncol. 2006;1:6.
31. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
32. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics. 2008;28:329-344.
33. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S-150S.
34. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol. 2006;24:3282-3292.
35. Galldiks N, Kracht LW, Burghaus L, et al. Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging. 2010;9:40-46.
36. Schwarzenberg J, Czernin J, Cloughesy TF, et al. 39-deoxy-39-18F- fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012;53:29-36.
37. Takaya S, Hashikawa K, Turkheimer FE, et al. The lack of expression of the peripheral benzodiazepine receptor characterises microglial response in anaplastic astrocytomas. J Neurooncol. 2007;85:95-103.
38. Gabrusiewicz K, Ellert-Miklaszewska A, Lipko M, Sielska M, Frankowska M, Kaminska B. Characteristics of the alternative phenotype of microglia/ macrophages and its modulation in experimental gliomas. PLoS ONE. 2011;6:e23902.
39. Yosifov DY, Todorov PT, Zaharieva MM, et al. Erucylphospho-N,N,N- trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity. Cancer Chemother Pharmacol. 2011;67:13-25.